Notice of Results

Oxford, UK - 24 February 2012: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, today announces that it will be releasing its preliminary results for the twelve months ended 31 December 2011 on Tuesday, 6 March 2012.

An analyst briefing will be held at 09:30am GMT on Tuesday, 6 March 2012 at the offices of M:Communications, 11th Floor, CityPoint, 1 Ropemaker Street, London, EC2Y 9AW.

Simultaneously to the analyst briefing at 09:30am GMT, there will be a live audio webcast of the presentation. To connect to the webcast facility, please visit the Company's website: www.oxfordbiomedica.co.uk approximately 10 minutes (9:20am GMT) before the start of the briefing. A replay will be made available shortly after the presentation.

- Ends -

For further information, please contact:

Oxford BioMedica plc:

Lara Mott, Head of Corporate Communications

Tel: +44 (0)1865 783 000

Media Enquiries:

Mary Clark/Claire Dickinson

M:Communications

Tel: +44 (0)20 7920 2342

Notes to editors

1. Oxford BioMedica

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, VIRxSYS, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk.